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formulated albumin-bound paclitaxel (nab-paclitaxel) in 
combination with gemcitabine also resulted in a significant 
survival extension compared to gemcitabine monotherapy. 
However, both intensified therapy regimens show a broad 
spectrum of side effects and patients need to be carefully 
selected for the most appropriate protocol.  Key Message: 
In this study, recent advances in the chemotherapeutic op-
tions available to treat metastatic PDAC and their implica-
tions for today’s treatment choices are reviewed. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Pancreatic ductal adenocarcinoma (PDAC) is consid-
ered to be one of the most lethal solid organ tumour. The 
extraordinarily poor prognosis can be attributed to the 
lack of early clinical symptoms and good biomarkers, ear-
ly metastatic dissemination and an unusually high resis-
tance to targeted and cytotoxic agents. The incidence of 
pancreatic cancer ranges worldwide from 1 to 10 cases per 
100,000, out of which 85% are adenocarcinomas  [1] . The 
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 Abstract 
 Background: Pancreatic ductal adenocarcinoma (PDAC) is 
characterised by an extremely poor overall survival (OS) 
compared to other solid tumours. As the incidence of the 
disease is rising and the treatment options are limited, PDAC 
is projected to be the 2nd leading cause of cancer-related 
deaths in the United States by 2030. A majority of patients 
are not eligible for curative resection at the time of diagnosis, 
and those that are resected will often relapse within the first 
few years after surgery.  Summary: Until recently, the nucleo-
side analogue gemcitabine has been the standard of care for 
patients with non-resectable PDAC with only marginal ef-
fects on OS. In 2011, the gemcitabine-free FOLFIRINOX regi-
men (folinic acid, fluorouracil, irinotecan and oxaliplatin) 
showed a significant survival advantage for patients with 
metastatic PDAC in a phase III trial. In 2013, the Metastatic 
Pancreatic Adenocarcinoma Trial phase III trial with nano-
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incidence is slightly higher in developed countries, among 
men, and a number of risk factors as well as genetic syn-
dromes/mutations that are associated with pancreatic 
cancer have been identified  [1, 2] . The genetic hallmark 
of PDAC is an activating KRAS mutation, followed by the 
deletion or the inactivation of mutations in tumour-sup-
pressor genes such as p16, DPC4 and p53  [3–5] . Extensive 
experimental studies in mice and men have identified and 
characterised a molecular and histological progression 
model ranging from early to advanced precursor lesions 
(so called pancreatic intraepithelial neoplasia lesions, 
PanIN I–III), to frank adenocarcinoma. Moreover, PDAC 
is typically accompanied by an extensive desmoplastic 
stroma reaction contributing to a hypovascular and hy-
poxic microenvironment, which possibly affects the de-
livery and efficacy of chemotherapeutic agents, repro-
gramming of cellular metabolism and evasion of tumour 
immunity  [6–8] .
 Clinical symptoms of PDAC patients are often very 
unspecific and hard to detect early. Patients may com-
plain of abdominal discomfort (with no signs of perito-
neal irritation), weight loss, painless jaundice and unspe-
cific back pain  [9, 10] . Onset of type II diabetes as well 
as unexplained deep vein thrombosis may also indicate 
the development of PDAC, but also occur for many other 
reasons in the elderly. Once the diagnosis of PDAC is 
 suspected, a multi-modal diagnostic work-up using mo-
dalities such as sonography, endosonography, multi-slice 
CT as well as MRI should be performed in a multi-disci-
plinary team. In case of a metastatic disease, histological 
confirmation prior to cytotoxic treatment is obligatory. 
Surgical resection is the only potentially curative treat-
ment and criteria of surgical resectability are based on 
the  involvement of the local vessels  [11] and presence 
or absence of metastatic disease. Until now, only about 
20–25% of patients are eligible for surgical resection. Cur-
rent treatment standards advocate the use of adjuvant 
chemotherapy following surgery. For locally advanced 
pancreatic adenocarinomca (LAPC), there is growing in-
terest in the use of neoadjuvant approaches, which are 
being evaluated, as in the currently recruiting Conko 007 
trial (EUDRACT Nr. 2009-014476-21). This phase III tri-
al is evaluating the role of a combined chemoradiothera-
py after leading-in with chemotherapy in patients with 
LAPC, interestingly already making use of FOLFIRINOX 
as a potential treatment arm. The currently enrolling 
NEONAX-trial, a phase II trial conducted by the AIO 
(EUDRACT-Nr. 2013-005559-34), is addressing the 
question of whether or not a neoadjuvant combination 
treatment with nab-paclitaxel and gemcitabine plus adju-
vant or only adjuvant gemcitabine and nab-paclitaxel 
treatment can downstage the tumour prior to surgery in 
patients with resectable PDAC ( table 1 ). Despite numer-
ous clinical trials in stage IV (metastatic) PDAC, there has 
only been a modest improvement of median survival 
rates for this group of patients  [12–15] . In the last 2 de-
cades, biomarker discovery and validation has been a key 
area of research to stratify patients, predict response to 
treatment and enable the development of a tailored treat-
ment approach. The aim of this review is to provide a 
comprehensive overview of the development of chemo-
therapeutic regimens that have been used for the treat-
ment of metastatic PDAC with a particular focus on the 
recently introduced gemcitabine-free FOLFIRINOX reg-
imen (folinic acid, fluorouracil, irinotecan and oxalipla-
tin) and nab-paclitaxel + gemcitabine.
Table 1.  Currently recruiting and ongoing clinical phase III trials with intensive chemotherapy
Design Compound/specifics Clinical trial
Adjuvant
Gemcitabine + nab vs. gemcitabine NCT01964430
Gemcitabine vs. FOLFIRINOX NCT02355119
Gemcitabine vs. mFOLFIRINOX NCT01526135
Neoadjuvant
Surgery + gemcitabine adjuvant vs. FOLFIRINOX neoadjuvant – 
surgery – FOLFIRINOX adjuvant NCT02172976
Surgery + PEXG adjuvant vs. PEXG neoadjuvant + surgery + adjuvant 
vs. gemcitabine adjuvant NCT01150630
Palliative 1st-line
Gemcitabine vs. FOLFOX hENT1 expression NCT01586611
Gemcitabine + nab + ibrutinib vs. gemcitabine + nab Bruton’s tyrosine kinase inhibitor NCT02436668
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 Current Management of Metastatic Disease 
 From 5-Fluorouracil to Gemcitabine 
 5-Fluorouracil (5-FU) was considered the only che-
motherapeutic option for about 20 years until the intro-
duction of gemcitabine  [13, 16–18] . Several clinical stud-
ies could show that chemotherapy in advanced pancre-
atic cancer patients indeed leads to a modest survival 
benefit as well as improved quality of life (QoL) com-
pared to best supportive care alone  [19–21] , but the com-
bination of 5-FU with other drugs did not prove to be 
superior to the single anti-metabolite treatment  [16, 22] . 
During the 1990s, several trials were designed to find 
new  active drugs in pancreatic cancer treatment and 
the   nucleoside analogue gemcitabine (2 ′ -deoxy-2 ′ ,2 ′ -
difluorocytinide) was studied  [12, 23] . In 1997, gem-
citabine became the first line choice for PDAC patients 
due to fewer side effects (compared to 5-FU) and a sig-
nificant survival benefit ( table 2 ). This clinical study also 
implemented the concept of clinical benefit response 
(CBR) that was defined as a  ≥ 50% reduction in pain in-
tensity, daily analgesia consumption or  ≥ 20 point im-
provement in Karnofsky performance status (PS) for  ≥ 4 
consecutive weeks. CBR was significantly improved in 
gemcitabine-treated patients (p = 0.0022)  [13] . The CBR 
was shown to be 23.8% in gemcitabine-treated patients 
(1,000 mg/m 2 over 30 min) compared to 4.8% in 5-FU-
treated patients (400 mg/m 2 over 30 min), and the me-
dian survival time in the gemcitabine group was 5.65 
months compared to 4.41 months in the 5-FU-group, 
 respectively (p = 0.0025). In the gemcitabine group, 18% 
compared to 2% for the 5-FU survived the first 12 months 
 [13] . Several phase III trials with gemcitabine monother-
apy revealed a median survival of 5–7 months with a 
Table 2.  The evolution of approved therapeutic regimens in patients with metastatic PDAC
Burris et al. 1997 Moore et al. 2007 Conroy et al. 2011 Von Hoff et al. 2013
Regimen Gemcitabine vs. 
5-FU
Gemcitabine + erlotinib vs. 
gemcitabine
Gemcitabine vs. 
FOLFIRINOX
Gemcitabine vs. gemcitabine 
+ nab
Number of patients 126 569 342 861
Population Advanced PDAC Advanced PDAC
(24.3% LAPC)
(~8% prior resection of 
 primary tumour)
Metastatic PDAC Metastatic PDAC
Characteristics
Biliary stent Not mentioned Not mentioned 15.8% 17%
Head tumors Not mentioned Not mentioned 39.2% 43%
ECOG/Karnofsky PS PS 80–90~30%
PS 50–70~70%
ECOG 0–1~80%
ECOG 2~20%
ECOG 0–1~99
ECOG 2~1%
PS 90–100~60%
PS 60–90~40%
Objective response rate, % 5.4 vs. 0 8.6 vs. 8 9.4 vs. 31.6 7 vs. 23
Disease control rate, % 44.4 vs. 19 57.5 vs. 49.2 50.9 vs. 70.2 33 vs. 48
mPFS/TTP* 9 vs. 4 w* 3.75 vs. 3.55 m 3.3 vs. 6.4 m 3.7 vs. 5.5 m
mOS, m 5.65 vs. 4.41 6.24 vs. 5.91 6.8 vs. 11.1 6.7 vs. 8.5
Survival rates 12 m, % 18 vs. 2 23 vs. 17 20.6 vs. 48.4 22 vs. 35
Treatment effect in 
subgroup analyses
Not mentioned PS 2, HR 0.61 
Pain-Score <20, HR 0.71
Age <65, HR 0.75
Age >65, HR 0.48
ECOG 1, HR 0.55
Two metastatic sites HR 0.39
No biliary stent HR 0.56
Age <65, HR 0.65
PS 70–80%, HR 0.61
Liver mets HR 0.69
CA 19–9 >59 ULN, HR 0.61
Specifics CBR – More female in the 
combination arm
– Female associated with 
longer OS
– ‘French-only’ study
– ~15% not radiologically 
 evaluable
– 38% head tumours
– Only ‘North Americans’ 
benefited
– 42% head tumours
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1-year survival of about 1–25%. Therefore, subsequent 
chemotherapy trials in PDAC needed to show superiori-
ty over standard of care gemcitabine monotherapy. This 
could be achieved by either of the 2 strategies: (1) combin-
ing gemcitabine with a new drug or (2) directly compar-
ing a novel monotherapy or combination therapy against 
gemcitabine.
 Gemcitabine and Fluoropyrimidines 
 While the results of gemcitabine clearly improved 
therapeutic efficacy and 1-year survival, its impact on me-
dian overall survival (OS) remained at the margin of sig-
nificance. More intensive combination chemotherapies 
involving fluoropyrimidines and platinum analogues 
were investigated in numerous phase II and III trials. Two 
randomised phase III trials evaluated the combination of 
gemcitabine and 5-FU compared to gemcitabine alone. 
In short, the experimental arm did not improve the objec-
tive response or median OS  [24, 25] .
 Capecitabine is an oral, tumour-selective fluoropyrim-
idine carbamate and pro-drug that is activated by a 3-step-
targeted process (carboxylesterases, cytidine deaminase 
and thymidine phosphorylase, respectively). Capecitabine 
can be used in schedules that provide prolonged fluoro-
uracil exposure at lower peak concentrations, thus mim-
icking continuous infusion of fluorouracil. Preclinical 
studies have shown no synergistic effect of capecitabine 
anti-tumour activity when combined with gemcitabine; 
however, relevant toxicity was noted in genetically engi-
neered mice of pancreatic cancer more recently  [26] . 
 Herrmann and Cunningham published 2 randomised 
phase III trials of gemcitabine +/– capecitabine (650 or 
830 mg/m 2 twice daily) in patients with metastatic PDAC. 
There was no statistically significant improvement of the 
median OS in the combination arm (8.4 vs. 7.2 m and 7.4 
vs. 6.0 m; p = 0.234 and p = 0.08). However, a subgroup 
of patients with good PS (Karnofsky performance score 
90–100) benefited (10.1 vs. 7.4 months, respectively; p = 
0.014) from the combination treatment. In addition, in 
the Cunningham et al.  [27] study, gemcitabine and 
capecitabine significantly improved the response rate 
(RR) (19.1 vs. 12.4%, p = 0.034) and progression-free sur-
vival (HR 0.78, p = 0.004). Interestingly, by pooling the 
data set of these 2 phase III trials and the phase II trial of 
Schreithauer in 935 patients, statistical significance could 
be achieved for median OS (HR 0.86; 95% CI 0.75–0.98, 
p = 0.02)  [19, 20, 28] . Independently from this data, Hub-
ner et al.  [29] presented single-centre results of the gem-
citabine plus capecitabine combination, leading to a me-
dian OS of 8.7 m (95% CI 6.7–10.7) and 1-year survival 
rate of 34%. Despite the fact that gemcitabine combined 
with fluoropyrimidine has reliable activity in metastatic 
PDAC, the QoL did not significantly differ between the 
2 treatment arms  [29–31] . Based on this data, the combi-
nation GEMCAP has replaced 5-FU therapy in clinical 
practice, especially in the United Kingdom.
 Gemcitabine in Combination with 
Platinum-Derivates and Topoisomerase Inhibitors 
 There have been numerous phase II and III studies at-
tempting to improve the efficacy and OS of chemothera-
py in metastatic PDAC by using gemcitabine-based com-
bination therapies. The combination of gemcitabine with 
platinum-derivates was evaluated in 11 trials in more 
than 2,000 patients  [31] . One of the most promising trials 
was the GERCOR/GISCAD study where the combination 
of gemcitabine and oxaliplatin improved the PFS (5.58 vs. 
3.7 months), CBR (38.2 vs. 26.9%) and RR (26.8 vs. 
17.3%). However, no statistical significance was reached 
for OS  [32] and the subsequent phase III trials did not 
confirm these encouraging results  [33–35] . A recently 
published meta-analysis compared gemcitabine plus ox-
aliplatin with gemcitabine alone. Here, ORs of 1.33 (95% 
CI 1.05–1.69, p = 0.019) for OS and ORs of 1.38 (95% CI 
1.08–1.76, p = 0.011) for PFS demonstrated and showed 
statistical significance  [19, 20, 28, 31] .
 Similar results were obtained for gemcitabine and 
topoisomerase inhibitors (irinotecan and exatecan) com-
binations. Although preliminary data suggested a rele-
vant clinical activity for topoisomerase inhibitors, 4 ran-
domised clinical trials revealed no significant improve-
ment of PFS or OS  [36–39] . Finally, in the Cancer and 
Leukemia Group B (CALGB) study, 3 relevant combina-
tion therapies (gemcitabine plus cisplatin, gemcitabine 
plus docetaxel, gemcitabine plus irinotecan) vs. gem-
citabine monotherapy demonstrated no relevant 6-month 
survival benefit for the experimental arms  [36] . There-
fore, the authors made a decision to refrain from fur-
ther  investigating gemcitabine-based combinations for 
PDAC.
 Gemcitabine and Erlotinib 
 The epidermal growth factor receptor inhibitor erlo-
tinib was the first drug that was shown to be beneficial in 
combination with gemcitabine in patients with advanced 
pancreatic cancer ( table 2 ). In the PA.3 trial, 569 patients 
were randomised with both locally advanced and meta-
static disease to receive gemcitabine or gemcitabine plus 
erlotinib. Though OS was significantly improved with 
combination therapy (median survival of 6.2 vs. 5.9 
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months), clinical relevance of a 2-week survival benefit 
had to be questioned  [40] . This marginal benefit also 
came at the expense of toxicity with 6 treatment-related 
deaths reported during the study – all within the combi-
nation therapy group. Eight patients from the study 
(7  from the erlotinib cohort) also developed interstitial 
lung disease and the risk-benefit of this drug combination 
remains a controversial topic  [41] .
 Interestingly, the combination of erlotinib and gem-
citabine achieved astonishing response in a small subset 
of patients. It was noted that those patients developing a 
rash of grade  ≥ 2 in severity showed a median survival of 
10.5 months and 1-year survival of 43% in contrast with 
5.3 months and 16% respectively in patients with no rash. 
Therefore, the German S3-guideline for exocrine pancre-
atic cancer recommends an initial therapeutic attempt 
with erlotinib and gemcitabine for an 8-week period. Af-
ter this time, treatment should be continued only if a skin 
rash develops  [11] . This interesting finding could be re-
capitulated in another study by Vaccaro et al.  [42] ; how-
ever, dose-escalation did not yield further therapeutic ef-
ficacy.
 Folinic Acid, Fluorouracil, Irinotecan and Oxaliplatin 
(FOLFIRINOX) 
 Several studies were performed to investigate gem-
citabine-based polychemotherapy regimens comprising 
several cytotoxic drugs. The PEFG protocol compared 
cisplatin, epirubicin, 5-FU and gemcitabine to gem-
citabine alone  [43] . The same group introduced another 
2, 4-drug combinations based on the PEFG regimen 
called PEXG (cisplatin, epirubicin, capecitabine and gem-
citabine) and PDGX (cisplatin, docetaxel, capecitabine 
and gemcitabine). Although median OS of 11 m were 
reached in this phase II study, the results were interpreted 
with caution, since only 2/3 of the patients had metastat-
ic disease  [44] . Another regimen called G-FLIP com-
prised CPT-11 (irinotecan), gemcitabine, 5-FU, leucovo-
rin and cisplatin  [45] , and subsequently FOLFOX-6 and 
FOLFIRI-3 were evaluated in the first-line setting of ad-
vanced PDAC  [46, 47] . Despite median OS times between 
8 and 12 months and higher RRs, increased major toxici-
ties, the inhomogeneity of the patient cohorts and the in-
sufficient inclusion criteria gave rise to doubts whether 
polychemotherapy was the adequate treatment strategy.
 FOLFIRINOX is a chemotherapy regimen comprising 
4 drugs – folinic acid, 5-FU, irinotecan and oxaliplatin. 
This combination of drugs was supported by preclinical 
studies demonstrating either single agent efficacy against 
pancreatic cancer or synergistic activity in combination 
with a fellow agent. Based on ambitious phase I/II data in 
which FOLFIRINOX revealed a good safety profile and 
appealing RRs, Conroy et al.  [48] conducted a French 
phase II/III trial (PRODIGE) with OS as primary objec-
tive, and PFS, QoL, RR and toxicity as secondary end-
points  [48, 49] . In total, 342 patients were enrolled and 
FOLFIRINOX was administered with the following dose: 
oxaliplatin at a dose of 85 mg/m 2 over 2 h followed by 
leucovorin at a dose of 400 mg/m 2 given as a 2-hour in-
travenous infusion and irinotecan at a dose of 180 mg/m 2 
in a 90-minute intravenous infusion  [50] . This treat-
ment  was immediately followed by 5-FU at a dose of 
400 mg/m 2 , administered by intravenous bolus, followed 
by a continuous intravenous infusion of 2,400 mg/m 2 
over a 46-hour period every 2 weeks. The patients on 
 FOLFIRINOX demonstrated a median survival of 11.1 
months, which was clearly superior when compared to 
the 6.8 months of the gemcitabine control group ( table 2 ). 
The median progression-free survival was 6.4 months in 
 FOLFIRINOX-treated patients versus 3.3 months in pa-
tients who received gemcitabine  [50] . Compared to treat-
ment with gemcitabine, treatment with FOLFIRINOX 
 resulted in a superior tumour RR (9.4 vs. 31.6%); how-
ever, 50 patients (25 per arm) were not radiologically 
 assessable. Yet in 2005, this regime showed promising re-
sults, when it had been administered to a heterogeneous 
group of patients just defined as histologically proven ad-
vanced PDAC, but containing both LAPC and metastatic 
PDAC. Thus, the treatment regimen was not exclusively 
restricted to patients suffering from metastatic disease 
 [48] . However, in order to achieve the benefits shown, the 
FOLFIRINOX regimen requires a careful selection of pa-
tients, which implicates strict limitations as the potential 
real-life first line option. In the study by Conroy et al., 
only patients with nearly unrestricted ECOG-PS of 0–1, 
below 76 years of age, no cardiac ischemia within 1 year 
before entry, and total bilirubin levels below 1.5 times the 
upper normal limit were included. Interestingly, only 35–
40% suffered from a pancreatic head adenocarcinoma 
and therefore, solely 15% received stenting of the biliary 
duct. No single cholangitis had been observed during the 
course of the trial. This difference may be related to the 
exclusion of patients with elevated bilirubin levels, be-
cause of the increased risk of irinotecan-induced toxicity 
 [51] . As shown by Conroy et al., even de-escalation (n = 
80 received second-line treatment in the FOLFIRINOX 
arm) might be necessary; yet it resulted in an impressive 
median OS of 4.4 months from the beginning of second-
line chemotherapy. Particularly, this accounts as one ex-
planation for the 1-year survival rate of 48.4% for patients 
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treated with FOLFIRINOX versus 20.6% for patients re-
ceiving gemcitabine (p < 0.001). Despite the strict selec-
tion criteria for the study, patients on FOLFIRINOX suf-
fered more frequently from adverse events or severe side 
effects compared to the patients on gemcitabine. Forty 
five percent of the FOLFIRINOX patients developed neu-
tropenia and 5.4% showed febrile neutropenia. In addi-
tion, thrombocytopenia (9.1%), diarrhea (12.7%) and 
sensory neuropathy (9.0%) occurred significantly more 
often in FOLFIRINOX patients, which implies a need for 
increased clinical routine check-up intervals for patients 
receiving this intensive regime. Moreover, supportive 
therapies such as nutritional support, G-CSF treatment 
or antibiotics are more often needed, and the discontinu-
ation of the therapy may be required. However, G-CSF 
was not recommended in this trial to prevent neutrope-
nia. Two years after the publication of the primary study 
data, QoL evaluations were presented  [52] . Although 
 FOLIRINOX had remarkable side effects, it significantly 
reduced QoL impairment compared with gemcitabine in 
patients with metastatic PDAC. Only diarrhea was sig-
nificantly increased in the FOLFIRINOX arm. Beyond 
the PS, age >65 years and low serum albumin were seen 
as independent prognostic factors for poor survival in 
this situation.
 Gemcitabine and Nab-Paclitaxel 
 In 2013, a second intensified combination-chemo-
therapy regimen – gemcitabine with nab-paclitaxel – was 
presented for the treatment of patients suffering from 
metastatic PDAC Metastatic Pancreatic Adenocarcino-
ma Trial (MPACT-Trial).
 Nab-paclitaxel is a nanoparticle-sized, albumin-bound 
paclitaxel, which was originally developed to avoid toxic 
and immunogenic solvents of hydrophobic paclitaxel, 
and was first approved by the FDA in breast cancer pa-
tients in 2005  [7, 53–57] .
 In PDAC, Von Hoff et al.  [53, 54] demonstrated in a 
phase II trial that patients with SPARC (secreted protein 
acidic and rich in cysteine) positive tumours revealed a 
highly significant benefit in OS when treated with gem-
citabine plus nab-paclitaxel. Therefore, it was hypothe-
sised that stromal SPARC as an albumin-binding protein 
would bind albumin-coated paclitaxel molecules, thereby 
selectively increasing drug delivery. However, preclinical 
data with genetically ablated SPARC mice showed com-
parable nab-paclitaxel concentrations within the endog-
enous murine pancreatic tumours compared to neo-
plasms overexpressing SPARC  [58] . Controversial data in 
men and mice exist regarding the potential of nab-pacli-
taxel to deplete abundant tumour stroma in PDAC  [55, 
59, 60] . Therefore, it remains questionable whether nab-
paclitaxel exerts any tumour-selective/targeted effect be-
yond its cytotoxicity as a mitotic inhibitor.
 Nevertheless, the international multi-centre MPACT-
trial revealed significant clinical benefits, achieving dis-
ease control rates of 67% in treated patients and a median 
OS of 8.5 months  [53, 54, 61] ( table 2 ).
 MPACT trial patients (n = 431) receiving the combi-
nation treatment of gemcitabine plus nab-paclitaxel 
showed a 1-year survival rate of 35 vs. 22% when com-
pared to the gemcitabine monotherapy group (n = 430), 
and 9% compared to 4% at the second year of follow-up. 
Moreover, a median progression-free survival of 5.5 
months in the combination therapy cohort versus 3.7 
months in the gemcitabine monotherapy group had been 
achieved. Severe neutropenia was significantly more fre-
quent in the combination therapy group of the MPACT 
trial (gemcitabine + nab-paclitaxel: 38%, gemcitabine: 
27%), while febrile neutropenia occurred in 3% of the pa-
tients. The same was true for the incidence of fatigue (17 
vs. 7%) and neuropathy (17 vs. 1%) that occurred signifi-
cantly more often in the nab-paclitaxel group than in the 
gemcitabine monotherapy group  [53] .
 Strikingly, immunohistochemical analysis from 
MPACT phase III patients failed to confirm that SPARC 
is a prognostic biomarker  [62] , confirming the earlier 
published preclinical data  [58] .
 In a recently published phase-III-trial (n = 861 pa-
tients) by Goldstein et al.  [63] , analysing the long-term-
survival of patients receiving the nab-paclitaxel plus gem-
citabine combination-treatment, the superior OS and 
PFS could be confirmed. Moreover, subgroup analysis 
emphasised the relevance of CA 19–9 and neutrophil to 
lymphocyte ratio as reasonable prognostic markers. High 
CA 19–9 levels and neutrophil to lymphocyte ratio before 
treatment was associated with a worse OS. Survivors of 
more than 3 years were exclusively identified in the nab-
paclitaxel plus gemcitabine arm (4%)  [63] . By performing 
post-hoc analyses of the MPACT collective, Tabernero et 
al.  [64] described PS score, liver metastases, age and num-
ber of metastatic sites as consistent and valid predictors 
of survival that are easily available clinical markers that 
help in decision making regarding treatment.
 Notably, a retrospective analysis showed that the eligi-
bility criteria itself for both the PRODIGE and MPACT 
trial, were associated with an improved survival  [65] . The 
authors demonstrated that patients who simply fulfilled 
the inclusion criteria for either FOLFIRINOX or nab-pa-
clitaxel/gemcitabine, without actually receiving the treat-
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ments, had a better median OS compared to patients who 
failed to meet them. When comparing the FOLFIRINOX-
eligible population with the nab-paclitaxel-eligible group, 
it becomes apparent that ECOG 2 patients were excluded 
in the FOLFIRINOX trial. These results were consistent 
with the fact that eligibility was no longer a significant 
prognostic factor after accounting for patient’s ECOG 
performance. Strictly following the trials inclusion crite-
ria, the authors demonstrated that the majority of pa-
tients with metastatic PDAC were not eligible for either 
of the intensified polychemotherapeutic regimens. Com-
paring only eligibility for treatment for nab-paclitaxel 
plus gemcitabine versus the FOLFIRINOX protocol, 
nearly twice as many patients could have been candidates 
for nab-paclitaxel due to less restrictive ECOG perfor-
mance criteria for this regimen in trials  [65] .
 Furthermore, novel drug formulations that improve 
the pharmacokinetic properties of hydrophobic paclitax-
el have been investigated. For instance, Löhr et al.  [66] 
have shown in a phase II trial that paclitaxel embedded in 
cationic liposomes, the so-called EndoTAG-1, was gener-
ally well tolerated and achieved a median OS of 8.1–9.3 
months when combined with gemcitabine.
 Ongoing clinical trials are investigating nab-paclitaxel 
as the backbone for novel targeted therapies. Examples 
are ruxolitinib, a janus-kinase inhibitor in combination 
with gemcitabine or nab-paclitaxel plus gemcitabine 
(NCT01822756), INCB039110 a JAK1 inhibitor in com-
bination with nab-paclitaxel plus gemcitabine 
(NCT01858883), or the indoleamine-2,3-dioxygenase in-
hibitor Indoximod in combination with nab-paclitaxel 
plus gemcitabine in advanced PDAC (NCT02077881). 
Those results might help to optimise the selection of ad-
equate patient cohorts eligible for nab-paclitaxel, and 
moreover provide additional insights into novel targeted 
treatment avenues ( table 1 ).
 Conclusion 
 It is evident from the existing data that there is a sig-
nificant survival benefit of intensive chemotherapy treat-
ment regimens FOLFIRINOX and gemcitabine + nab-
paclitaxel for metastatic PDAC. Although OS rates may 
be overestimated due to very stringent enrolment crite-
ria for these trials, national and international guidelines 
recommend them as first-line therapy for metastatic 
PDAC. However, careful patient selection based on clini-
cal and laboratory findings represents a major challenge 
for physicians and oncologists in the palliative situation 
( fig. 1 ). Currently, no biomarker can reliably predict the 
response to treatment to nab-paclitaxel + gemcitabine 
or FOLFIRINOX. Therefore, a careful clinical and bio-
chemical follow-up is required to optimise the treatment 
effects while minimising the side effects. Often, dose re-
ductions are a feasible approach to cope with the en-
hanced toxicity profile of these protocols. For the future, 
intensified chemotherapies such as nab-paclitaxel and 
FOLFIRINOX may also be extended to selected patients 
with LAPC in a neoadjuvant setting, as well as for adju-
vant treatment strategies. Furthermore, intensified che-
motherapy protocols are currently investigated as back-
bone for novel investigational PDAC therapies, such as 
anti-stromal approaches or immune cell checkpoint an-
tagonists.
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